NGM·Healthcare·$346M·#305 / 520 in Healthcare
SLN Silence Therapeutics Plc - Amer
38HIGH RISK
CATEGORY BREAKDOWN
GROWTH0
QUALITY52
STABILITY36
VALUATION0
GOVERNANCE94
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
-98.7%
0
> 50% strong
Gross Margin
Revenue retained after direct costs
61.5%
87
> 50% strong
Cash Runway
Months of cash at current burn rate
2 months
4
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
0.3%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
616.8x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
-16155
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
24.4%
92
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
-66.7%
100
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE SLN WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when SLN's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.